Journal of the American Chemical Society
Page 8 of 10
B(OH)2
A
B
F
F
1
F
2
3
4
5
5b (2.5 equiv)
O
O
O
O
SPhosPdG3 (5 mol %)
CsF (3 equiv)
CO2t-Bu
CO2t-Bu
N
N
Br
DMF, H2O
80 °C, 12 h
12
13 95%
F
6
7
F
F
8
9
0.1 M aq
NaOH
2 M aq HCl
OH OH
OH OH
CO2Na
CO2H
H
N
N
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
THF, rt, 16 h
THF, rt, 5 h
N
14 88%
(atorvastatin mimic)
atorvastatin
F
O
Figure 2. (A) Synthesis of a fluoroalkene mimic of atorvastatin 14 and evaluation of its HMGꢀCoA reductase inhibitory effect. (B) Doseꢀ
response curves with Hill slopes (252 sec after treatment of HMGꢀCoA reductase), showing that atorvastatin and 14 inhibited HMGꢀCoA
reductase activity with IC50 values of 162 nM and 655 nM, respectively. See the Supporting Information for details.
317, 1881–1886. (c) Gillis, E. P.; Eastman, K. J.; Hill, M. D.; Donnelꢀ
ly, D. J.; Meanwell, N. A. J. Med. Chem. 2015, 58, 8315–8359, and
■
ASSOCIATED CONTENT
references cited therein.
(2) (a) CouveꢀBonnaire, S.; Cahard, D.; Pannecoucke, X. Org. Bi-
omol. Chem. 2007, 5, 1151–1157. (b) Taguchi, T.; Yanai, H. In Fluo-
rine in Medicinal Chemistry and Chemical Biology; Ojima, I. Ed.;
Blackwell Publishing Inc: Malden, 2009; pp 257–290.
(3) Fluoropolymers 1: Synthesis in Topics in Applied Chemistry;
Hougham, G., Cassidy, P. E., Johns, K., Davidson, T., Eds.; Kluwer
Academic/Plenum Publishers: New York, 2002.
(4) For recent reviews, see: (a) Landelle, G.; Bergeron, M.; Turꢀ
cotteꢀSavard, M.ꢀO.; Paquin, J.ꢀF. Chem. Soc. Rev. 2011, 40, 2867–
2908. (b) Yanai, H.; Taguchi, T. Eur. J. Org. Chem. 2011, 5939–5954.
(c) Zhang, X.; Cao, S. Tetrahedron Lett. 2017, 58, 375–392.
(5) For pioneering works, see: (a) Dixon, S. J. Org. Chem. 1956,
21, 400–403. (b) Tarrant, P.; Heyes, J. J. Org. Chem. 1965, 30, 1485–
1487.
(6) (a) Yamada, S.; Noma, M.; Hondo, K.; Konno, T.; Ishihara, T.
J. Org. Chem. 2008, 73, 522–528. (b) Ohashi, M.; Kamura, R.; Doi,
R.; Ogoshi, S. Chem. Lett. 2013, 42, 933–935.
(7) For ipsoꢀborylation via aromatic C–F bond cleavage, see: (a)
Liu, X.ꢀW.; Echavarren, J.; Zarate, C.; Martin, R. J. Am. Chem. Soc.
2015, 137, 12470−12473. (b) Niwa, T.; Ochiai, H.; Watanabe, Y.;
Hosoya, T. J. Am. Chem. Soc. 2015, 137, 14313–14318. (c) Mfuh, A.
M.; Doyle, J. D.; Chhetri, B.; Arman, H. D.; Larionov, O. V. J. Am.
Chem. Soc. 2016, 138, 2985–2988. (d) Zhou, J.; KuntzeꢀFechner, M.
W.; Bertermann, R.; Paul, U. S. D.; Berthel, J. H. J.; Friedrich, A.; Du,
Z.; Marder, T. B.; Radius, U. J. Am. Chem. Soc. 2016, 138, 5250−
5253. (e) Niwa, T.; Ochiai, H.; Hosoya, T. ACS Catal. 2017, 7, 4535–
4541.
Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website.
Experimental procedures, characterization for new compounds,
including copies of NMR spectra.
■
AUTHOR INFORMATION
Corresponding Authors
*takashi.niwa@riken.jp
*ogoshi@chem.eng.osakaꢀu.ac.jp
*takamitsu.hosoya@riken.jp
Author Contribution
§H.S. and Y.U. contributed equally.
Notes
The authors declare no competing financial interest.
■
ACKNOWLEDGMENTS
The authors thank Dr. Isao Kii, Ms. Rie Sonamoto, and Ms.
Harumi Ito at RIKEN CLST for their kind support on the
HMGꢀCoA reductase inhibition assay. This research was supꢀ
ported by the Platform Project for Supporting Drug Discovery
and Life Science Research funded by Japan Agency for Mediꢀ
cal Research and Development (AMED) (T.H. and T.N.);
JSPS KAKENHI Grant Numbers 17H03057 and 16KT0057
(M.O.), 15H03118 (T.H. and T.N), 16H01133 (Middle Molecꢀ
ular Strategy; T.H.), 15K05509 (T.N.), 16H02276 (S.O.); the
Cooperative Research Project of Research Center for Biomedꢀ
ical Engineering (T.H.); the Sasakawa Scientific Research
Grant from The Japan Science Society (Y.U.). H.S. is grateful
for support as a JSPS Research Fellow.
(8) For metalative C(sp2)–F bond cleavage, see: (a) Braun, T.;
Noveski, D.; Neumann, B.; Stammler, H.ꢀG. Angew. Chem., Int. Ed.
2002, 41, 2745–2748. (b) Yamada, S.; Takahashi, T. Konno T.; Ishiꢀ
hara, T. Chem. Commun. 2007, 3679–3681. (c) Brisdon, A. K.;
Pritchard, R. G.; Thomas, A. Organometallics 2012, 31, 1341–1348.
(d) Ohashi, M.; Shibata, M.; Saijo, H.; Kambara, T.; Ogoshi, S. Or-
ganometallics 2013, 32, 3631–3639. (e) Ohashi, M.; Saijo, H.; Shibata,
M.; Ogoshi, S. Eur. J. Org. Chem. 2013, 443–447.
(9) For synthesis of metalated fluoroalkenes, see ref 8 and: (a)
McCarthy, J. R.; Huber, E. W.; Le, T.ꢀB.; Laskovics, F. M.; Matꢀ
thews, D. P. Tetrahedron 1996, 52, 45–58. (b) Wnuk, S. F.; Garcia, P.
I., Jr.; Wang, Z. Org. Lett. 2004, 6, 2047–2049. (c) Wang, Z.; Gonzaꢀ
lez, A.; Wnuk, S. F. Tetrahedron Lett. 2005, 46, 5313–5316.
(10) For recent reviews, see: (a) Ohashi, M.; Ogoshi, S. Top. Or-
ganomet. Chem. 2015, 52, 197–215. (b) Ohashi, M.; Ogoshi, S. J.
Synth. Org. Chem. Jpn. 2016, 74, 1047–1057.
■
REFERENCES
(1) (a) Swallow, S. In Fluorine in Pharmaceutical and Medicinal
Chemistry: From Biophysical Aspects to Clinical Applications; Gouꢀ
verneur, V., Müller, K., Ed.; Imperial Collage Press: London, 2012;
pp 141–174. (b) Müller, K.; Faeh, C.; Diederich, F. Science 2007,
(11) (a) Saijo, H.; Ohashi, M.; Ogoshi, S. J. Am. Chem. Soc. 2014,
136, 15158–15161. (b) Kikushima, K.; Sakaguchi, H.; Saijo, H.;
Ohashi, M.; Ogoshi, S. Chem. Lett. 2015, 44, 1019–1021.
ACS Paragon Plus Environment